Multiple instance learning to predict immune checkpoint blockade efficacy using neoantigen candidates
Franziska LangiD, Patrick SorniD, Barbara SchrörsiD, David Weber, Stefan KrämeriD, Uğur ŞahiniD, Martin Löwer
Abstract
A successful response to immune checkpoint blockade treatment (ICB) depends on the functional re-invigoration of neoantigen-specific T cells and their anti-tumoral activity. Previous studies showed that the patients neoantigen candidate load is an imperfect predictor of the response to ICB. Further studies provided evidence that the overall response to ICB is also affected by the qualitative properties of a few or even single candidates, limiting the predictive power based on candidate quantity alone. To our knowledge, this is the first study to predict the response to ICB therapy based on qualitative neoantigen candidate profiles in the context of the mutation type, using a multiple instance learning approach. Multiple instance learning is a special branch of machine learning which classifies labelled bags that are formed by a set of unlabeled instances. The multiple instance learning approach performed systematically better than random guessing and was independent of the neoantigen candidate load. Qualitative modeling performed better in comparison to the quantitative approach, in particular for modelling low-abundant fusion genes. Our findings suggest that multiple instance learning is an appropriate method to predict immunotherapy efficacy based on qualitative neoantigen candidate profiles without relying on direct T-cell response information and provide a foundation for future developments in the field.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- FWCI
- 0.36
- Field percentile
- top 42%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Integrated germline and somatic features reveal divergent immune pathways driving ICB response
Timothy J. Sears, Meghana S. Pagadala, … Hannah K. Carter·Cancer Immunology ResearchPeer-reviewed·Sep 10, 2024
- Is tumor mutational burden predictive of response to immunotherapy?
Carino Gurjao, Dina I. Tsukrov, … Leonid A. Mirny·bioRxiv·Sep 3, 2020
- HINS: HLA-mediated immunogenic neoantigen score for robust prediction of immune checkpoint blockade response
Qiang Yang, Long Xu, … Guohua Wang·bioRxiv·Dec 12, 2025
- Improving T-cell mediated immunogenic epitope identification via machine learning: the neoIM model
Lena Pfitzer, Lien Lybaert, … Bruno Fant·bioRxiv·Jun 3, 2022
- NeoPrecis: Enhancing Immunotherapy Response Prediction through Integration of Qualified Immunogenicity and Clonality-Aware Neoantigen Landscapes
Ko-Han Lee, Timothy J. Sears, … Hannah K. Carter·Nature CommunicationsPeer-reviewed·Jan 23, 2026
- MHC-I binding affinity derived metrics fail to predict tumor specific neoantigen immunogenicity
Guadalupe Nibeyro, María Romina Girotti, … Elmer A. Fernández·bioRxiv·Mar 14, 2022